DiaMedica Therapeutics (DMAC)
(Real Time Quote from BATS)
$2.59 USD
+0.06 (2.37%)
Updated Apr 26, 2024 03:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Brokerage Reports
DiaMedica Therapeutics, Inc. [DMAC]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Join our Call Today at 11AM to Unlock the Potential of DM199 in CKD and Stroke
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
|